CAS 1609564-75-1

DY268

CAS: 1609564-75-1

1-(3-Methoxybenzyl)-N-(4-methyl-3-(morpholinosulfonyl)phenyl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide

Fórmula: C₃₀H₃₂N₄O₅S

Pureza: 98%

Peso molecular: 560.66

Ref: IN-DG00796363

DY268

CAS: 1609564-75-1

Fórmula: C₃₀H₃₂N₄O₅S

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 560.6639

Ref: IN-DA01E2HF

DY268

CAS: 1609564-75-1

DY268

Fórmula: C₃₀H₃₂N₄O₅S

Pureza: ≥98%

Peso molecular: 560.66

Ref: 54-BUP08020

DY268

CAS: 1609564-75-1

DY268 is a compound based on trisubstituted pyrazolamide without any FXR agonist activity and cytotoxicity and can be used as an effective FXR antagonist.

Fórmula: C₃₀H₃₂N₄O₅S

Pureza: 99.43% - 99.75%

Cor e Forma: Solid

Peso molecular: 560.66

Ref: TM-T31587

DY 268

Produto Controlado

CAS: 1609564-75-1

Fórmula: C₃₀H₃₂N₄O₅S

Cor e Forma: Neat

Peso molecular: 560.664

Ref: TR-D824900

DY 268

CAS: 1609564-75-1

DY 268 is a coumarin derivative that binds to the prostate-specific membrane antigen (PSMA) and is being developed as a treatment for prostate cancer. This compound has been shown to inhibit the transport rate of PSMA, which prevents it from binding to the receptor. DY 268 has also been shown to be an effective adjuvant therapy for chronic inflammatory diseases such as rheumatoid arthritis. DY 268 was activated in human liver cells, and its growth factor activity was found to be localized in proximal tubules.

Fórmula: C₃₀H₃₂N₄O₅S

Pureza: Min. 95%

Peso molecular: 560.66 g/mol

Ref: 3D-JPC56475